Recent Advances in the Development of Innovative Anticancer Agents and Antitumor Strategies
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 28 February 2027 | Viewed by 639
Editors
Interests: medicinal chemistry; drug discovery; synthetic organic chemistry; anticancer agents; multitarget-directed ligands; polypharmacology; hybrid compounds; prodrugs; mutual prodrugs; 5-fluorouracil; HO-1 inhibitors; sigma receptor ligands; 5-HT7 receptor ligands
Special Issues, Collections and Topics in MDPI journals
Interests: medicinal chemistry; drug discovery; heterocyclic compounds synthesis; serotonin; 5-HT ligands; anticancer agents
Special Issues, Collections and Topics in MDPI journals
Interests: supramolecular chemistry; nanomaterials; chromophores; supramolecular nanoassemblies; organic-inorganic hybrid functional nanomaterials; spectroscopy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is a major type of noncommunicable disease that still represents one of the most frequent causes of death globally. Major challenges in current cancer research include the difficulty of diagnosis and treatment, both of which can highly affect clinical outcomes. Among several reasons for increased incidence and mortality, the most frequent ones are severe side effects and therapeutic resistance. Consequently, given the heterogeneity and multifaceted complexity of cancer etiology and pathophysiology, it stands to reason that its treatment requires multimodal approaches, along with the development of both innovative anticancer agents and pharmaceutical strategies with enhanced efficacy and safety profiles.
In light of these challenges, this Special Issue is intended to provide insights into the recent developments in cancer research, highlighting the potential impact in the field. We welcome original research papers, insightful review articles, and impactful short communications dealing with the development of novel strategies for cancer treatment. In particular, submissions that focus on a wide range of anticancer approaches, dealing with medicinal chemistry, pharmaceutics, and supramolecular strategies, are welcome. These include, but are not limited to, the design, synthesis, and biological evaluation of active small molecules, polypharmacological agents, hybrid compounds, conjugates, prodrugs, and fluorescent probes, as well as the development of controlled drug delivery systems and supramolecular nanoassemblies, including organic–inorganic hybrid nanomaterials for drug delivery and cancer theranostics. We look forward to hearing from you.
Dr. Sebastiano Intagliata
Dr. Elisa Magli
Dr. Mariachiara Trapani
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anticancer strategies
- anticancer agents
- drug design
- drug development
- chemical synthesis
- small molecules
- drug delivery
- prodrugs
- hybrid compounds
- multitarget ligands
- conjugate derivatives
- polypharmacology
- hybrid nanoassemblies
- nanoparticles
- supramolecular systems
- theranostics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
